샘플 요청 목록

 카트 문의
시장보고서
상품코드
1446442

북미 분자진단 시장 - 규모, 점유율, 동향 분석 보고서 : 제품별, 검사 부위별, 기술별, 용도별, 국가별, 부문별 예측(2024-2030년)

North America Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Others), By Test Location, By Technology (PCR, ISH, INAAT, Sequencing), By Application, By Country, And Segment Forecasts, 2024 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

북미의 분자진단 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 북미의 분자진단 시장 규모는 2024년부터 2030년까지 연평균 복합 성장률(CAGR) 4.2%를 기록했으며, 2030년에는 72억 3,000만 달러에 달할 것으로 예측되고 있습니다.

기술적으로 첨단 제품의 소개가 북미 시장을 견인할 것으로 기대됩니다. 분자진단기술의 진보는 많은 질병의 조기 발견을 가능하게 하고, 심각한 경제적·사회적 부담의 가능성을 감소시켰습니다. 분자진단 기술은 PCR, 시퀀싱, 유전자 기술을 이용하여 암, 유전성 질환, 감염증의 조기 진단을 가능하게 합니다.

알츠하이머병, 터너 증후군, 파킨슨병 등의 만성 질환 및 감염증, 유전성 질환의 유병률 증가는 예측 기간 동안 시장 수요를 높일 것으로 예상됩니다. CDC에 따르면 미국에서는 매년 암과 당뇨병, 만성 신장병 및 호흡기 질환 등의 만성 질환이 10명에 7명의 사망 원인이 되고 있습니다. 게다가 A형·B형 인플루엔자와 같은 질병 증가도 시장 성장을 가속할 것으로 예측되고 있습니다. 예를 들어, CDC에 따르면 2021-2022년 인플루엔자 시즌에는 900만 명이 독감을 앓고 있다고 추정됩니다.

분자진단에서 임상 연구를 수행하기 위한 외부 자금 증가는 시장 활성화로 이어질 것으로 예상됩니다. 자금 조달은 제품 개발 프로세스에서 중요한 역할을 합니다. 예를 들어 2023년 4월 Promega Corporation은 qPCR을 이용한 학술생명과학 연구에 2023년에 1만 5,000달러를 조성한다고 발표했습니다. 마찬가지로 2023년 6월 Accelerate Diagnostics, Inc.는 Wave 플랫폼과 신규 신속검사 개발을 가속화하기 위해 2,400만 달러를 받았습니다. 이러한 노력으로 중소기업이 신규분자진단검사의 개발에 관여할 것으로 기대됩니다.

주요 기업은 북미의 분자진단에서 신제품을 상시하고 보다 고도로 효율적인 제품으로 변화하는 구매자의 요구를 충족시켜 경쟁력을 획득하기 위해 지속적인 노력을 하고 있습니다. 예를 들어, 2022년 11월, Danahaer의 자회사인 Cepheid는 트리코모나스증, 세균성 질염, 외음질 칸디다증 등 다양한 질환을 검출하는 PCR 검사인 Multiplex Vaginal Panel(MVP)을 출시했습니다.

또한 새로운 치료제 개발을 위한 제조업체와 기업 간의 전략적 파트너십 증가가 시장 성장을 가속할 것으로 예상됩니다. 예를 들어, 2023년 2월, Thermo Fisher Scientific Inc.는 결핵 및 HIV와 같은 다양한 감염을 위한 RT-PCR 키트를 조달하기 위해 MyLab과 제휴했습니다. 또한 2023년 1월 QIAGEN과 Helix는 유전자 질환에서 차세대 시퀀서의 동반진단을 강화하기 위해 독점적 제휴를 맺었습니다.

북미의 분자진단 시장 보고서 하이라이트 :

  • 제품별로, 2023년 북미의 분자진단에서 가장 큰 판매 점유율을 차지한 것은 효율성과 비용 효율성 향상을 통한 시약 부문였습니다.
  • 2023년 북미의 분자진단 시장은 중앙 검사실 부문이 높은 시장 침투율과 대규모 검사 건수에 의해 지배적이었습니다.
  • 기술별로는 PCR 분야가 2023년 북미의 분자진단 시장에서 우위를 차지하고 임상 진단에서 의사와 환자들 사이에서 가장 선호되는 기술입니다.
  • 감염증 분야는 북미의 감염증 이환율이 높아 2023년 용도 분야를 선도했습니다.
  • 미국은 유리한 상환 정책, 대기업의 현지 진출, 확립된 헬스케어 인프라의 존재로 이 지역 시장을 독점하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향 및 범위

  • 시장 계통 전망
    • 상위 시장 전망
    • 관련/부수 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 업계 분석 툴
    • Porter's Five Forces 분석
    • PESTEL 분석
    • COVID-19 감염의 영향 분석

제4장 북미의 분자진단 시장 : 제품 비즈니스 분석

  • 북미의 분자진단 시장 : 제품의 변동 분석
  • 기기
  • 시약
  • 기타

제5장 북미의 분자진단 시장 : 검사 장소의 비즈니스 분석

  • 북미의 분자진단 시장 : 검사 장소의 변동 분석
  • 포인트 오브 케어
  • 셀프 테스트 또는 매장 테스트
  • 중앙연구소

제6장 북미의 분자진단 시장 : 기술 비즈니스 분석

  • 북미의 분자진단 시장 : 기술 변동 분석
  • PCR
  • In Situ 하이브리드화(ISH)
  • 등온 핵산 증폭 기술(INAAT)
  • 칩과 마이크로어레이
  • 질량 분석
  • 시퀀싱
  • 전사 매개 증폭(TMA)
  • 기타

제7장 북미의 분자진단 시장 : 용도 비즈니스 분석

  • 북미의 분자진단 시장 : 용도 변동 분석
  • 종양학
  • 약리 유전체학
  • 감염증
  • 유전자 검사
  • 신경질환
  • 순환기 질환
  • 미생물학
  • 기타

제8장 북미의 분자진단 시장 : 국가별 비즈니스 분석

  • 북미
    • 미국
    • 캐나다

제9장 북미의 분자진단 시장 : 경쟁 구도

  • 참가 기업
    • BD
    • Bio-Rad Laboratories, Inc.
    • Abbott
    • Agilent Technologies, Inc.
    • Danaher
    • Hologic Inc.(Gen Probe)
    • Illumina, Inc.
    • Johnson & Johnson Services, Inc.
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche, Ltd.
  • 참가 기업의 개요
  • 재무실적
  • 제품 벤치마킹
  • 기업의 시장 점유율 분석, 2023년
  • 전략 매핑

제10장 애널리스트의 시점

JHS 24.03.25

North America Molecular Diagnostics Market Growth & Trends:

The North America molecular diagnostics market size is expected to reach USD 7.23 billion by 2030, registering a CAGR of 4.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The introduction of technologically advanced products is expected to drive the market in North America. Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens. Molecular diagnostics enable early diagnosis of cancer, genetic disorders, and infectious diseases by using PCR, sequencing, & genetic technologies.

The rise in the prevalence of chronic & infectious diseases and genetic disorders, such as Alzheimer's disease, Turner syndrome, & Parkinson's disease, is expected to boost the market demand during the forecast period. According to the CDC, chronic diseases such as cancer & diabetes and chronic kidney & respiratory diseases are accountable for 7 in 10 deaths in the U.S. each year. Around 6 out of 10 adults are likely to suffer from a chronic disease in the U.S. In addition, the increasing incidence of diseases, such as influenza A & B, is projected to drive market growth. For instance, according to the CDC, in the flu season of 2021-2022, influenza was estimated to affect nine million people.

An increase in external funding to conduct clinical studies in molecular diagnostics is anticipated to fuel the market. Funding plays a significant role in the product development process. For instance, in April 2023, Promega Corporation announced to grant of USD 15,000 in 2023 in academic life sciences research using qPCR. Similarly, in June 2023, Accelerate Diagnostics, Inc. received USD 24 million to accelerate the development of Wave platform and novel rapid testing. Such initiatives are expected to encourage SMEs to be involved in the development of novel molecular diagnostic tests.

Key companies are making continuous efforts to launch new products in North America molecular diagnostics and gain a competitive edge by meeting the changing needs of buyers toward more advanced & efficient products. For instance, in November 2022, Cepheid, a Danaher subsidiary, launched Multiplex Vaginal Panel (MVP), a PCR test to detect various conditions, such as trichomoniasis, bacterial vaginosis, and vulvovaginal candidiasis.

Furthermore, increasing strategic partnerships among manufacturers and companies for developing novel therapeutics is anticipated to drive market growth. For instance, in February 2023, Thermo Fisher Scientific Inc.partnered with MyLab to procure RT-PCR kits for various infectious diseases, such as tuberculosis & HIV. Moreover, in January 2023, QIAGEN and Helix formed an exclusive alliance to enhance next-generation sequencing companion diagnostics in genetic disorders.

North America Molecular Diagnostics Market Report Highlights:

  • Based on the product, the reagents segment accounted for the largest revenue share of North America molecular diagnostics in 2023 owing to improved efficiency and cost-effectiveness
  • The central laboratories segment dominated the North America molecular diagnostics in 2023 owing to high market penetration and large procedure volumes
  • Based on technology, the PCR segment dominated the North America molecular diagnostics in 2023 and is the most preferred technology amongst doctors and patients for clinical diagnostics
  • The infectious disease segment led the application segment in 2023, attributable to North America's high incidence of infectious diseases
  • The U.S. dominated the regional market due to favorable reimbursement policies, the local presence of leading players, and the presence of well-established healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product segment
      • 1.1.1.2. Test Location segment
      • 1.1.1.3. Technology segment
      • 1.1.1.4. Application segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Test Location Snapshot
  • 2.3. Technology and Application Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increase in geriatric population
      • 3.2.1.2. Introduction of technologically advanced products
      • 3.2.1.3. Increase in demand for point-of-care testing
      • 3.2.1.4. Growing prevalence of target diseases
      • 3.2.1.5. Increasing external funding for R&D
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of ambiguous regulatory framework
      • 3.2.2.2. High prices of molecular diagnostics tests
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. North America Molecular Diagnostics Market: Product Business Analysis

  • 4.1. North America Molecular Diagnostics Market: Product Movement Analysis
  • 4.2. Instruments
    • 4.2.1. Instruments Market, 2018 - 2030 (USD Million)
  • 4.3. Reagents
    • 4.3.1. Reagents Market, 2018 - 2030 (USD Million)
  • 4.4. Others
    • 4.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. North America Molecular Diagnostics Market: Test Location Business Analysis

  • 5.1. North America Molecular Diagnostics Market: Test Location Movement Analysis
  • 5.2. Point-of-Care
    • 5.2.1. Point-of-Care Market, 2018 - 2030 (USD Million)
  • 5.3. Self-test or Over the Counter
    • 5.3.1. Self-test or Over the Counter Market, 2018 - 2030 (USD Million)
  • 5.4. Central Laboratories
    • 5.4.1. Central Laboratories Market, 2018 - 2030 (USD Million)

Chapter 6. North America Molecular Diagnostics Market: Technology Business Analysis

  • 6.1. North America Molecular Diagnostics Market: Technology Movement Analysis
  • 6.2. PCR
    • 6.2.1. PCR Market, 2018 - 2030 (USD Million)
      • 6.2.1.1. PCR, by Type
      • 6.2.1.1.1. PCR, by Type Market, 2018 - 2030 (USD Million)
      • 6.2.1.1.1.1. Multiplex PCR
      • 6.2.1.1.1.1.1. Multiplex PCR Market, 2018 - 2030 (USD Million)
      • 6.2.1.1.1.2. Other PCR
      • 6.2.1.1.1.2.1. Other PCR Market, 2018 - 2030 (USD Million)
      • 6.2.1.2. PCR, by Procedure
      • 6.2.1.2.1. PCR, by Procedure Market, 2018 - 2030 (USD Million)
      • 6.2.1.2.1.1. Nucleic Acid Extraction
      • 6.2.1.2.1.1.1. Nucleic Acid Extraction Market, 2018 - 2030 (USD Million)
      • 6.2.1.2.1.2. Others
      • 6.2.1.2.1.2.1. Others Market, 2018 - 2030 (USD Million)
      • 6.2.1.3. PCR, by Product
      • 6.2.1.3.1. PCR, by Product Market, 2018 - 2030 (USD Million)
      • 6.2.1.3.1.1. Instruments
      • 6.2.1.3.1.1.1. Instruments Market, 2018 - 2030 (USD Million)
      • 6.2.1.3.1.2. Reagents
      • 6.2.1.3.1.2.1. Reagents Market, 2018 - 2030 (USD Million)
      • 6.2.1.3.1.3. Others
      • 6.2.1.3.1.3.1. Others Market, 2018 - 2030 (USD Million)
  • 6.3. In Situ Hybridization (ISH)
    • 6.3.1. In Situ Hybridization (ISH) Market, 2018 - 2030 (USD Million)
    • 6.3.2. Instruments
      • 6.3.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.3.3. Reagents
      • 6.3.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.3.4. Others Market, 2018 - 2030 (USD Million)
      • 6.3.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
    • 6.4.1. Isothermal Nucleic Acid Amplification Technology (INAAT) Market, 2018 - 2030 (USD Million)
    • 6.4.2. Instruments
      • 6.4.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.4.3. Reagents
      • 6.4.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.4.4. Others Market, 2018 - 2030 (USD Million)
      • 6.4.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.5. Chips and Microarrays
    • 6.5.1. Chips and Microarrays Market, 2018 - 2030 (USD Million)
    • 6.5.2. Instruments
      • 6.5.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.5.3. Reagents
      • 6.5.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.5.4. Others Market, 2018 - 2030 (USD Million)
      • 6.5.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.6. Mass Spectroscopy
    • 6.6.1. Mass Spectroscopy Market, 2018 - 2030 (USD Million)
    • 6.6.2. Instruments
      • 6.6.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.6.3. Reagents
      • 6.6.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.6.4. Others Market, 2018 - 2030 (USD Million)
      • 6.6.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.7. Sequencing
    • 6.7.1. Sequencing Market, 2018 - 2030 (USD Million)
    • 6.7.2. Instruments
      • 6.7.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.7.3. Reagents
      • 6.7.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.7.4. Others Market, 2018 - 2030 (USD Million)
      • 6.7.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.8. Transcription Mediated Amplification (TMA)
    • 6.8.1. Transcription Mediated Amplification (TMA) Market, 2018 - 2030 (USD Million)
    • 6.8.2. Instruments
      • 6.8.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.8.3. Reagents
      • 6.8.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.8.4. Others Market, 2018 - 2030 (USD Million)
      • 6.8.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market, 2018 - 2030 (USD Million)
    • 6.9.2. Instruments
      • 6.9.2.1. Instruments Market, 2018 - 2030 (USD Million)
    • 6.9.3. Reagents
      • 6.9.3.1. Reagents Market, 2018 - 2030 (USD Million)
    • 6.9.4. Others Market, 2018 - 2030 (USD Million)
      • 6.9.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. North America Molecular Diagnostics Market: Application Business Analysis

  • 7.1. North America Molecular Diagnostics Market: Application Movement Analysis
  • 7.2. Oncology
    • 7.2.1. Oncology Market, 2018 - 2030 (USD Million)
    • 7.2.2. Breast Cancer
      • 7.2.2.1. Breast Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.3. Prostate Cancer
      • 7.2.3.1. Prostate Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.4. Colorectal Cancer Market, 2018 - 2030 (USD Million)
      • 7.2.4.1. Colorectal Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.5. Cervical Cancer
      • 7.2.5.1. Cervical Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.6. Kidney Cancer
      • 7.2.6.1. Kidney Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.7. Liver Cancer Market, 2018 - 2030 (USD Million)
      • 7.2.7.1. Liver Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.8. Blood Cancer
      • 7.2.8.1. Blood Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.9. Lung Cancer
      • 7.2.9.1. Lung Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.10. Other Cancer Market, 2018 - 2030 (USD Million)
      • 7.2.10.1. Other Cancer Market, 2018 - 2030 (USD Million)
  • 7.3. Pharmacogenomics
    • 7.3.1. Pharmacogenomics Market, 2018 - 2030 (USD Million)
  • 7.4. Infectious Diseases
    • 7.4.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
    • 7.4.2. Methicillin-resistant Staphylococcus Aureus (MRSA)
      • 7.4.2.1. Methicillin-resistant Staphylococcus Aureus (MRSA) Market, 2018 - 2030 (USD Million)
    • 7.4.3. Clostridium Difficile
      • 7.4.3.1. Clostridium Difficile Market, 2018 - 2030 (USD Million)
    • 7.4.4. Vancomycin-resistant Enterococci (VRE)
      • 7.4.4.1. Vancomycin-resistant Enterococci (VRE) Market, 2018 - 2030 (USD Million) Instruments
    • 7.4.5. Carbapenem-resistant Bacteria
      • 7.4.5.1. Carbapenem-resistant Bacteria Market, 2018 - 2030 (USD Million)
    • 7.4.6. Flu
      • 7.4.6.1. Flu Market, 2018 - 2030 (USD Million)
    • 7.4.7. Candida Market, 2018 - 2030 (USD Million)
      • 7.4.7.1. Candida Market, 2018 - 2030 (USD Million)
    • 7.4.8. Tuberculosis and Drug-resistant TBA
      • 7.4.8.1. Tuberculosis and Drug-resistant TBA Market, 2018 - 2030 (USD Million)
    • 7.4.9. Meningitis
      • 7.4.9.1. Meningitis Market, 2018 - 2030 (USD Million)
    • 7.4.10. Gastrointestinal Panel Testing
      • 7.4.10.1. Gastrointestinal Panel Testing Market, 2018 - 2030 (USD Million)
    • 7.4.11. Chlamydia
      • 7.4.11.1. Chlamydia Market, 2018 - 2030 (USD Million)
    • 7.4.12. Gonorrhea
      • 7.4.12.1. Gonorrhea Market, 2018 - 2030 (USD Million)
    • 7.4.13. HIV
      • 7.4.13.1. HIV Market, 2018 - 2030 (USD Million)
    • 7.4.14. Hepatitis C
      • 7.4.14.1. Hepatitis C Market, 2018 - 2030 (USD Million)
    • 7.4.15. Hepatitis B
      • 7.4.15.1. Hepatitis B Market, 2018 - 2030 (USD Million)
    • 7.4.16. Others Infectious Diseases
      • 7.4.16.1. Other Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 7.5. Genetic Testing
    • 7.5.1. Genetic Testing Market, 2018 - 2030 (USD Million)
    • 7.5.2. Newborn Screening
      • 7.5.2.1. Newborn Screening Market, 2018 - 2030 (USD Million)
    • 7.5.3. Predictive and Presymptomatic Testing
      • 7.5.3.1. Predictive and Presymptomatic Market, 2018 - 2030 (USD Million)
    • 7.5.4. Other Genetic Testing Market, 2018 - 2030 (USD Million) Instruments
      • 7.5.4.1. Other Genetic Testing Market, 2018 - 2030 (USD Million)
  • 7.6. Neurological Disease
    • 7.6.1. Neurological Disease Market, 2018 - 2030 (USD Million)
  • 7.7. Cardiovascular Disease
    • 7.7.1. Cardiovascular Disease Market, 2018 - 2030 (USD Million)
  • 7.8. Microbiology
    • 7.8.1. Microbiology Market, 2018 - 2030 (USD Million)
  • 7.9. Others
    • 7.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. North America Molecular Diagnostics Market: Country Business Analysis

  • 8.1. North America
    • 8.1.1. North America Molecular Diagnostics Market, 2018 - 2030 (USD Million)
    • 8.1.2. U.S.
      • 8.1.2.1. Key Country Dynamics
      • 8.1.2.2. Target Disease Prevalence
      • 8.1.2.3. Competitive Scenario
      • 8.1.2.4. Regulatory Framework
      • 8.1.2.5. U.S. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
    • 8.1.3. Canada
      • 8.1.3.1. Key Country Dynamics
      • 8.1.3.2. Target Disease Prevalence
      • 8.1.3.3. Competitive Scenario
      • 8.1.3.4. Regulatory Framework
      • 8.1.3.5. Canada Molecular Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 9. North America Molecular Diagnostics Market: Competitive Landscape

  • 8.1. Participant Categorization
    • 9.1.1. BD
      • 9.1.1.1. Overview
      • 9.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.1.3. Product Benchmarking
      • 9.1.1.4. Strategic Initiatives
    • 9.1.2. Bio-Rad Laboratories, Inc.
      • 9.1.2.1. Overview
      • 9.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.2.3. Product Benchmarking
      • 9.1.2.4. Strategic Initiatives
    • 9.1.3. Abbott
      • 9.1.3.1. Overview
      • 9.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.3.3. Product Benchmarking
      • 9.1.3.4. Strategic Initiatives
    • 9.1.4. Agilent Technologies, Inc.
      • 9.1.4.1. Overview
      • 9.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.4.3. Product Benchmarking
      • 9.1.4.4. Strategic Initiatives
    • 9.1.5. Danaher
      • 9.1.5.1. Overview
      • 9.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.5.3. Product Benchmarking
      • 9.1.5.4. Strategic Initiatives
    • 9.1.6. Hologic Inc. (Gen Probe)
      • 9.1.6.1. Overview
      • 9.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.6.3. Product Benchmarking
      • 9.1.6.4. Strategic Initiatives
    • 9.1.7. Illumina, Inc.
      • 9.1.7.1. Overview
      • 9.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.7.3. Product Benchmarking
      • 9.1.7.4. Strategic Initiatives
    • 9.1.8. Johnson & Johnson Services, Inc.
      • 9.1.8.1. Overview
      • 9.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.8.3. Product Benchmarking
      • 9.1.8.4. Strategic Initiatives
    • 9.1.9. Thermo Fisher Scientific Inc.
      • 9.1.9.1. Overview
      • 9.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.9.3. Product Benchmarking
      • 9.1.9.4. Strategic Initiatives
    • 9.1.10. F. Hoffmann-La Roche, Ltd.
      • 9.1.10.1. Overview
      • 9.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.1.10.3. Product Benchmarking
      • 9.1.10.4. Strategic Initiatives
  • 9.2. Participant's Overview
  • 9.3. Financial Performance
  • 9.4. Product Benchmarking
  • 9.5. Company Market Share Analysis, 2023
  • 9.6. Strategy Mapping
    • 9.6.1. Expansion
    • 9.6.2. Acquisition
    • 9.6.3. Product/Service Launch
    • 9.6.4. Others

Chapter 10. Analyst View

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제